Compass Therapeutics (NASDAQ:CMPX) Announces Earnings Results, Beats Estimates By $0.03 EPS

Compass Therapeutics (NASDAQ:CMPX) released its earnings results on Tuesday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03, Zacks reports.

Compass Therapeutics Stock Down 5.3 %

CMPX traded down $0.09 on Thursday, reaching $1.60. The company’s stock had a trading volume of 237,812 shares, compared to its average volume of 432,202. The company has a market capitalization of $220.14 million, a price-to-earnings ratio of -4.47 and a beta of 0.92. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.34. The stock has a 50 day moving average of $1.75 and a two-hundred day moving average of $1.42.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CMPX. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a report on Monday, September 16th. Finally, Wedbush reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, August 7th.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.